INS and type 2 diabetes mellitus: A study conducted in T2DM adults demonstrated that pioglitazone, at doses of 30 or 45 mg/day, caused a dose-dependent decrease in fasting and postprandial blood glucose concentrations through improvements in hepatic/whole-body insulin sensitivity and β cell function (14).